论文部分内容阅读
目的:探讨巨块型宫颈癌术前新辅助化疗(neoadjuvant chemotherapy,NACT)的疗效。方法:选择我院自2005年1月~2008年10月收治的30例1b-Ⅱb期、局部肿块≥4cm的巨块型宫颈癌患者,采用紫杉醇加顺铂(TP)方案行1~2个疗程的静脉化疗之后,全部患者均行广泛全子宫加盆腔淋巴结清扫术,观察其近期疗效。结果:本组30例巨块型宫颈癌应用NACT治疗,有效率CR+PR+MR)90%,手术切除率100%。结论:宫颈癌术前新辅助化疗是安全有效的,宫颈癌的新辅助化疗降低了临床分期、缩小了局部病灶、提高了手术切除率及成功率,延长患者的生存期。
Objective: To investigate the curative effect of preoperative neoadjuvant chemotherapy (NACT) for massive cervical cancer. Methods: Thirty patients with massive cervical cancer with stage 1b-Ⅱb and local mass≥4cm who were treated in our hospital from January 2005 to October 2008 were treated with paclitaxel plus cisplatin (TP) After treatment of intravenous chemotherapy, all patients underwent extensive uterine plus pelvic lymphadenectomy to observe the short-term efficacy. Results: The group of 30 cases of massive cervical cancer treated with NACT, effective CR + PR + MR) 90%, 100% surgical resection rate. Conclusion: Neoadjuvant chemotherapy for cervical cancer is safe and effective. Neoadjuvant chemotherapy of cervical cancer reduces the clinical stage, reduces the local lesion, increases the rate of resection and success, and prolongs the survival of patients.